Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05932732 · ClinicalTrials.gov registry record · Phase 4
Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.
A Phase 4 study of Cutis Laxa Facialis and Xeroderma, sponsored by Austin Institute for Clinical Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
- 2
- Study locations
NCT05932732: Completed Phase 4 study of Cutis Laxa Facialis and Xeroderma, sponsored by Austin Institute for Clinical Research.
NCT05932732 is a Phase 4 study of Cutis Laxa Facialis and Xeroderma that has completed, run by Austin Institute for Clinical Research. The registered enrollment target is 27 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05932732, a Phase 4 study of Cutis Laxa Facialis and Xeroderma, has completed, sponsored by Austin Institute for Clinical Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase IV, unblinded, open-label study assessing the impact on skin quality, hydration, and barrier of three (3) Hydrafacial treatments in healthy adults of Fitzpatrick Skin Types I \& II, III, IV, V \& VI, 30 to 55 years of age. Efficacy and subject satisfaction will be assessed, before and after three (3) HF treatments, in 6 patient cohorts, each cohort defined by FST I-VI.
Primary Outcome
Measured by Investigator assessment using the validated Scientific Assessment Scale of Skin Quality. the scale assesses the facial skin elasticity, wrinkles, roughness, fine lines, pigmentation, and erythema. The parameters include 0 = none (best possible outcome), 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe (worst possible outcome). Pore size will be measured using parameters of 0 = fine (best possible outcome), 1 = small, 2 = moderate, 3 = large, and 4 = very large (worst possible
Conditions Studied
Interventions
- DEVICE HydraFacial Syndeo System
- DRUG ReGen-GF
- DEVICE HydraFacial Elite MD System
Study Locations (2)
Texas
- Austin Institute for Clinical Research, Inc. - Houston
- Austin Institute for Clinical Research, Inc. - Pflugerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2023-11-20 |
| Est. Completion | 2024-10-09 |
| Phase | Phase 4 |
What the finished NCT05932732 record still lists
NCT05932732 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Cutis Laxa Facialis appearing as the primary indexed condition, and to 3 interventions - of which HydraFacial Syndeo System is the first listed.
NCT05932732 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05932732 about?
NCT05932732 is a clinical study titled "Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.". This is a phase IV, unblinded, open-label study assessing the impact on skin quality, hydration, and barrier of three (3) Hydrafacial treatments in healthy adults of Fitzpatrick Skin Types I \& II, III, IV, V \& VI, 30 to 55 years of age. Efficacy and subject satisfaction will be assessed, before an...
What is the current status of trial NCT05932732?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2023-11-20. Estimated completion is 2024-10-09.
What conditions does trial NCT05932732 study?
This clinical trial studies the following conditions: Cutis Laxa Facialis, Xeroderma.
What interventions are being tested in trial NCT05932732?
The interventions under investigation include: HydraFacial Syndeo System (DEVICE), ReGen-GF (DRUG), HydraFacial Elite MD System (DEVICE).
Who is sponsoring clinical trial NCT05932732?
This trial is sponsored by Austin Institute for Clinical Research, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05932732 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05932732's enrollment target sits among peer trials
27 1651st of 2000 higher than 346 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI